Announcements Trials
Browse Landscape

Phase

Phase 2 10Phase 1/2 4Phase 3 2Phase NA 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 3865Neoplasms 2991Prostatic Neoplasms 1754Colorectal Neoplasms 1431Lung Neoplasms 1332Motor Activity 805Head and Neck Neoplasms 686Pancreatic Neoplasms 664Colonic Neoplasms 655Uterine Cervical Neoplasms 653Carcinoma, Hepatocellular 632Carcinoma, Non-Small-Cell Lung 631Rectal Neoplasms 571Stomach Neoplasms 547Brain Neoplasms 486Ovarian Neoplasms 441Anxiety Disorders 420Pain 419Neoplasm Metastasis 385Esophageal Neoplasms 384Polycystic Ovary Syndrome 376Precursor Cell Lymphoblastic Leukemia-Lymphoma 354Urinary Bladder Neoplasms 351Fatigue 340Multiple Myeloma 323Melanoma 323Lymphoma 306Depression 306Endometrial Neoplasms 290Liver Neoplasms 280

Interventions

Prednisone 1PE regimen 1Injections 1Etoposide 1Docetaxel 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase NA × Hormone Refractory Prostate Cancer × Clear all
NCT02208583 2014-08-05

Molecular Phenotype Changes and Personalized Treatment for CRPC

Tianjin Medical University Cancer Institute and Hospital

Phase NA Unknown
150 enrolled
Genitourinary

Hormone Refractory Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡